Top

10-06-2018 | Healthcare costs | Article

A cost analysis of intensified vs conventional multifactorial therapy in individuals with type 2 diabetes: a post hoc analysis of the Steno-2 study

Journal: Diabetologia

Authors: Joachim Gæde, Jens Oellgaard, Rikke Ibsen, Peter Gæde, Emil Nørtoft, Hans-Henrik Parving, Jakob Kjellberg, Oluf Pedersen

Publisher: Springer Berlin Heidelberg

Abstract

Aims/hypothesis

Long-term follow-up of the Steno-2 study demonstrated that intensified multifactorial intervention increased median lifespan by 7.9 years and delayed incident cardiovascular disease by a median of 8.1 years compared with conventional multifactorial intervention during 21.2 years of follow-up. In this post hoc analysis of data from the Steno-2 study, we aimed to study the difference in direct medical costs associated with conventional vs intensified treatment.

Methods

In 1993, 160 Danish individuals with type 2 diabetes and microalbuminuria were randomised to conventional or intensified multifactorial target-driven intervention for 7.8 years. Information on direct healthcare costs was retrieved from health registries, and the costs in the two groups of participants were compared by bootstrap t test analysis.

Results

Over 21.2 years of follow-up, there was no difference in total direct medical costs between the intensified treatment group, €12,126,900, and the conventional treatment group, €11,181,700 (p = 0.48). The mean cost per person-year during 1996–2014 was significantly lower in the intensified treatment group (€8725 in the intensive group and €10,091 in the conventional group, p = 0.045). The main driver of this difference was reduced costs associated with inpatient admissions related to cardiovascular disease (p = 0.0024).

Conclusions/interpretation

Over a follow-up period of 21.2 years, we found no difference in total costs and reduced cost per person-year associated with intensified multifactorial treatment for 7.8 years compared with conventional multifactorial treatment. Considering the substantial gain in life-years and health benefits achieved with intensified treatment, we conclude that intensified multifaceted intervention in high-risk individuals with type 2 diabetes seems to be highly feasible when balancing healthcare costs and treatment benefits in a Danish healthcare setting.

Rao Kondapally Seshasai S, Kaptoge S, Thompson A et al (2011) Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med 364:829–841. https://doi.org/10.1056/NEJMoa1008862 CrossRefPubMedPubMedCentral

Huo L, Shaw JE, Wong E, Harding JL, Peeters A, Magliano DJ (2016) Burden of diabetes in Australia: life expectancy and disability-free life expectancy in adults with diabetes. Diabetologia 59:1437–1445. https://doi.org/10.1007/s00125-016-3948-x CrossRefPubMed

Loukine L, Waters C, Choi BC, Ellison J (2012) Impact of diabetes mellitus on life expectancy and health-adjusted life expectancy in Canada. Popul Health Metrics 10:7. https://doi.org/10.1186/1478-7954-10-7 CrossRef

Sortso C, Green A, Jensen PB, Emneus M (2016) Societal costs of diabetes mellitus in Denmark. Diab Med 33:877–885. https://doi.org/10.1111/dme.12965 CrossRef

Satman I, Omer B, Tutuncu Y et al (2013) Twelve-year trends in the prevalence and risk factors of diabetes and prediabetes in Turkish adults. Eur J Epidemiol 28:169–180. https://doi.org/10.1007/s10654-013-9771-5 CrossRefPubMedPubMedCentral

Li R, Lu W, Jiang QW et al (2012) Increasing prevalence of type 2 diabetes in Chinese adults in Shanghai. Diabetes Care 35:1028–1030. https://doi.org/10.2337/dc11-1212 CrossRefPubMedPubMedCentral

Gregg EW, Li Y, Wang J et al (2014) Changes in diabetes-related complications in the United States, 1990-2010. N Engl J Med 370:1514–1523. https://doi.org/10.1056/NEJMoa1310799 CrossRefPubMed

Gæde P, Oellgaard J, Carstensen B et al (2016) Years of life gained by multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: 21 years follow-up on the Steno-2 randomised trial. Diabetologia 59:2298–2307. https://doi.org/10.1007/s00125-016-4065-6 CrossRefPubMedPubMedCentral

Oellgaard J, Gaede P, Rossing P, Persson F, Parving HH, Pedersen O (2017) Intensified multifactorial intervention in type 2 diabetics with microalbuminuria leads to long-term renal benefits. Kidney Int 91:982–988. https://doi.org/10.1016/j.kint.2016.11.023 CrossRefPubMed

10.

Oellgaard J, Gaede P, Rossing P et al (2018) Reduced risk of heart failure with intensified multifactorial intervention in individuals with type 2 diabetes and microalbuminuria: 21 years of follow-up in the randomised Steno-2 study. Diabetologia 61:1724–1733. https://doi.org/10.1007/s00125-018-4642-y CrossRefPubMedPubMedCentral

11.

Gæde P, Valentine WJ, Palmer AJ et al (2008) Cost-effectiveness of intensified versus conventional multifactorial intervention in type 2 diabetes: results and projections from the Steno-2 study. Diabetes Care 31:1510–1515. https://doi.org/10.2337/dc07-2452 CrossRefPubMedPubMedCentral

12.

Gæde P, Vedel P, Parving HH, Pedersen O (1999) Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study. Lancet (London, England) 353:617–622. https://doi.org/10.1016/S0140-6736(98)07368-1 CrossRef

13.

Pedersen CB (2011) The Danish Civil Registration System. Scand J Public Health 39:22–25. https://doi.org/10.1177/1403494810387965 CrossRefPubMed

14.

Lynge E, Sandegaard JL, Rebolj M (2011) The Danish National Patient Register. Scand J Public Health 39:30–33. https://doi.org/10.1177/1403494811401482 CrossRefPubMed

15.

Rawshani A, Rawshani A, Franzen S et al (2017) Mortality and cardiovascular disease in type 1 and type 2 diabetes. N Engl J Med 376:1407–1418. https://doi.org/10.1056/NEJMoa1608664 CrossRefPubMed

16.

Tunceli K, Bradley CJ, Nerenz D, Williams LK, Pladevall M, Elston Lafata J (2005) The impact of diabetes on employment and work productivity. Diabetes Care 28:2662–2667. https://doi.org/10.2337/diacare.28.11.2662 CrossRefPubMed

17.

American Diabetes Association (2018) 9. Cardiovascular disease and risk management: standards of medical care in diabetes–2018. Diabetes Care 41(Suppl 1):S86–s104. https://doi.org/10.2337/dc18-S009 CrossRef

18.

Neal B, Perkovic V, Mahaffey KW et al (2017) Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 377:644–657. https://doi.org/10.1056/NEJMoa1611925 CrossRefPubMed

19.

Marso SP, Bain SC, Consoli A et al (2016) Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 375:1834–1844. https://doi.org/10.1056/NEJMoa1607141 CrossRefPubMed

20.

Marso SP, Daniels GH, Brown-Frandsen K et al (2016) Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 375:311–322. https://doi.org/10.1056/NEJMoa1603827 CrossRefPubMedPubMedCentral

21.

Zinman B, Wanner C, Lachin JM et al (2015) Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373:2117–2128. https://doi.org/10.1056/NEJMoa1504720 CrossRefPubMed

22.

American Diabetes Association (2018) 8. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes–2018. Diabetes Care 41(Suppl 1):S73–s85. https://doi.org/10.2337/dc18-S008 CrossRef

Be confident that your patient care is up to date

Medicine Matters is being incorporated into Springer Medicine, our new medical education platform.

Alongside the news coverage and expert commentary you have come to expect from Medicine Matters diabetes, Springer Medicine's complimentary membership also provides access to articles from renowned journals and a broad range of Continuing Medical Education programs. Create your free account »